SK Bioscience climbs two notches in ESG evaluation, receives BBB rating

The company's upgraded rating reflects its proactive efforts in enhancing the independence of its board and developing human resources

SK Bioscience climbs two notches in ESG evaluation, receives BBB rating
Jeong Min Nam 1
2023-02-03 15:54:39 peux@hankyung.com
ESG

SK Bioscience Co., a biopharmaceutical arm of South Korea's SK Group, announced it has received a BBB rating in its latest environmental, social, and governance (ESG) evaluation from Morgan Stanley Capital International (MSCI).

The 2022 evaluation saw the firm improve two steps from its previous B rating, which was given in 2021.

MSCI has been evaluating listed companies worldwide for ESG management capabilities and commitment to sustainability since 1999, using 35 key issues in 10 ESG categories as indicators.

The evaluation is considered a globally recognized indicator of a company's ESG management capabilities and commitment to sustainability.

SK Bioscience's upgraded rating reflects its proactive efforts in enhancing the independence of its board and developing human resources.

"ESG management is now a crucial aspect for all world-class companies, and we aim to be a global leader by prioritizing stakeholder satisfaction and creating a positive business environment to promote global public health," said SK Bioscience CEO Ahn Jae-yong.

Write to Jeong Min Nam at peux@hankyung.com
##SK Bioscience ##MSCI ESG #korea sk bioscience #sk bioscience msci esg

SK Bioscience's SKYCellflu approved by Chilean health authority

SK Bioscience's SKYCellflu approved by Chilean health authority

SK Bioscience's SKYCellflu SK Bioscience Co., a bio and pharmaceutical affiliate of South Korea's SK Group, announced on Thursday that its world-first cell culture-based quadrivalent influenza vaccine SKYCellflu has received approval from the Instituto de Salud Publica de Chile (Chilean Institu

SK Bioscience's shingles vaccine obtains product approval from Malaysia

SK Bioscience's shingles vaccine obtains product approval from Malaysia

SK Bioscience's Sky Zoster SK Bioscience Co. said on Monday that its shingles vaccine Sky Zoster has been given approval by Malaysia's National Pharmaceutical Regulatory Agency.Sky Zoster is a live attenuated vaccine developed by SK Bioscience with its proprietary technology and was approved

SK Inc. gets highest AAA grade in MSCI's ESG rating

SK Inc. gets highest AAA grade in MSCI's ESG rating

SK Inc., SK Group's investment arm, won the highest AAA ratings from both Morgan Stanley Capital International (MSCI) and the Dow Jones Sustainability Index (DJSI), both of which are environmental, social, and governance (ESG) rating agencies.The company said on Tuesday that it received its fi

SK Bioscience seeks WHO nod for prompt COVID vaccine sale

SK Bioscience seeks WHO nod for prompt COVID vaccine sale

SK Bioscience’s production line of SKYCovione in South Korea (Courtesy of Yonhap) SK Bioscience Co., the biopharmaceutical unit of South Korea’s No. 2 conglomerate SK Group, sought approval from the World Health Organization (WHO) for the immediate sale of the company’s COVID-
(* comment hide *}